PRISMASOLBGK2/0 (Baxter Healthcare Corporation)
Welcome to the PulseAid listing for the PRISMASOL drug offered from Baxter Healthcare Corporation. This Calculi Dissolution Agent [EPC],Magnesium Ion Exchange Activity [MoA],Osmotic Laxative [EPC],Osmotic Activity [MoA],Inhibition Small Intestine Fluid/Electrolyte Absorption [PE],Increased Large Intestinal Motility [PE],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Baxter Healthcare Corporation |
NON-PROPRIETARY NAME: | magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate, and potassium chloride |
SUBSTANCE NAME: | MAGNESIUM CHLORIDE; DEXTROSE MONOHYDRATE; LACTIC ACID, L-; SODIUM CHLORIDE; SODIUM BICARBONATE; POTASSIUM CHLORIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Calculi Dissolution Agent [EPC],Magnesium Ion Exchange Activity [MoA],Osmotic Laxative [EPC],Osmotic Activity [MoA],Inhibition Small Intestine Fluid/Electrolyte Absorption [PE],Increased Large Intestinal Motility [PE],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | SOLUTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2006-10-25 |
END MARKETING DATE: | 0000-00-00 |
PRISMASOL BGK2/0 HUMAN PRESCRIPTION DRUG Details:
Item Description | PRISMASOL BGK2/0 from Baxter Healthcare Corporation |
LABELER NAME: | Baxter Healthcare Corporation |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | .102; 1.1; .27; 6.136; 2.688; .149(g/L; g/L; g/L; g/L; g/L; g/L) |
START MARKETING DATE: | 2006-10-25 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 24571-102_de471206-dcf9-4219-8282-1d6e48141f93 |
PRODUCT NDC: | 24571-102 |
APPLICATION NUMBER: | NDA021703 |
Other MAGNESIUM CHLORIDE; DEXTROSE MONOHYDRATE; LACTIC ACID, L-; SODIUM CHLORIDE; SODIUM BICARBONATE; POTASSIUM CHLORIDE Pharmaceutical Manufacturers / Labelers: